The biomarker data provides incremental mechanistic support but does not change the regulatory or commercial timeline. Monitor for BLA submission timing and any FDA feedback on the phase 3 data package.
Price Chart
Executive Summary
Candel Therapeutics presented new biomarker data at ASTRO 2026 showing its lead candidate aglatimagene significantly increased lymphocyte infiltration and immune engagement in prostate tumors two years after treatment, supporting the previously reported phase 3 clinical benefit. The data strengthens the mechanistic rationale for the planned Biologics License Application submission, but the filing is a scientific presentation with no new regulatory or financial catalysts.
Key Facts
- AI-enabled digital pathology analysis of 622 pre-treatment and 427 post-treatment biopsies from phase 3 trial (NCT01436968) showed aglatimagene + EBRT significantly increased intratumoral lymphocyte infiltration vs placebo + EBRT
- 80% of evaluable aglatimagene patients had negative prostate biopsies at two years vs 63% for control (p=0.0018)
- Aglatimagene significantly increased overall lymphocytic fraction (p=0.048) and intratumoral lymphocyte fraction in residual tumor patients (p=0.006)
- Data presented at ASTRO 2026 on September 29, 2026; company plans BLA submission
- Aglatimagene has Fast Track and Regenerative Medicine Advanced Therapy designations from FDA for localized prostate cancer
Financial Impact
No financial data disclosed; clinical-stage company with no approved products or revenue
Risk Factors
- Aglatimagene is not yet approved by FDA or any regulatory authority
- Phase 3 data already reported; this is confirmatory biomarker analysis, not a new efficacy readout
- Clinical-stage biotech with no revenue and reliance on financing for BLA preparation
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371847 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | Press Release | $10.16 | awaiting T+60 | — | $7.79 (−23.33%) |
Sep 30, 2026 26d ago | Press Release | $10.44 | awaiting T+60 | — | $7.79 (−25.38%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $7.79 (−31.24%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $7.79 (−35.94%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $7.79 (−33.98%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $7.79 (−22.64%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $7.79 (−20.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers